Development of a Method for Identification and Quantification of Sulfadiazine and Pyrimethamine in Serum of Congenital Toxoplasmosis Pediatric Patients
- 1 área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina
- 2 Laboratorio UPL, Universidad Nacional de La Plata/Comisión de Investigaciones Científicas de la Provincia de Buenos Aires, La Plata, Argentina
- 3 Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP-CONICET), Servicio de Parasitología y Chagas, Hospital de Niños “Dr. Ricardo Gutiérrez”, Buenos Aires, Argentina
- 4 área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina
- 5 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), La Plata, Argentina
- 6 Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP-CONICET), Servicio de Parasitología y Chagas, Hospital de Niños “Dr. Ricardo Gutiérrez”, Buenos Aires, Argentina
- 7 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), La Plata, Argentina
- 8 Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western Ontario University, London, Ontario, Canada
- 9 área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina
Abstract
Infection with Toxoplasma gondii , is one of the most widespread zoonoses in the world. Congenital Toxoplasmosis (CT) is particularly risky due to its fetal complications. Sulfadiazine (SDZ) and Pyrimethamine (PYR) are usually used for CT treatment in Argentina, to prevent morbidity. Due to the lack of commercial pediatric formulations, these must be prepared in the hospital pharmacy. This is the first report of serum concentrations measures in pediatric CT therapy for this combination of drugs. A bioanalytical method was developed for identification and simultaneous quantification of SDZ and PYR by High Performance Liquid Chromatography (HPLC) with UV detection. The validated method was applied to residual serum samples obtained from 6 pediatric patients undergoing treatment with SDZ 42.20 a 93.70 mg/kg/day and PYR 0.77 a 2.70 mg/kg/day. Sample pretreatment consisted on a deproteini zation step followed by centrifugation and then injection of supernatant. Limit of Detection (LOD) and Quantification (LOQ) were (0.17 ± 0.02 and 0.13 ± 0.02) μg/mL and (0.46 ± 0.01 and 0.36 ± 0.01) μg/mL for SDZ and PYR respectively, with an appropriate linear range. Concentrations range found were (<LOD - 162.04 ± 0.02) μg/mL for SDZ and (<LOD - 7.30 ± 0.03) μg/mL for PYR. We developed and validated in real pediatric samples, an acute, pre cise and low-cost method for quantification of SDZ and PYR using a non-so phisticate chromatographic equipment, suitable for hospital therapeutic monitoring for public health system.
- Durlach, R., Kaufer, F., Carral, L., Freuler, C., Ceriotto, M., Rodríguez, M., et al. (2008) Consenso Argentino de Toxoplasmosis Congénita. Medicina (Buenos Aires), 68, 75-87.
- de Infectología, C. (1999) Consenso de infecciones perinatales. Argentine Archive of Pediatrics, 97, 33-37.
- McAuley, J., Boyer, K.M., Patel, D., Mets, M., Swisher, C., Roizen, N., Wolters, C., Stein, L., Stein, M., Schey, W., Remington, J., Meier, P., Johnson, D., Heydeman, P., Holfels, E., Withers, S., Mack, D., Brown, C., Patton, D. and McLeod, R. (1994) Early and Longitudinal Evaluations of Treated Infants and Children and Untreated Historical Patients with Congenital Toxoplasmosis: The Chicago Collaborative Treatment Trial. Clinical Infectious Diseases, 18, 38-72. https://doi.org/10.1093/clinids/18.1.38
- Altcheh, J., Diaz, N.S., Pepe, C.M., Martin, V., Nigro, M., Freilij, H. and Angel, S.O. (2006) Kinetic Analysis of the Humoral Immune Response Against 3 Toxoplasma gondii-Recombinant Proteins in Infants with Suspected Congenital Toxoplasmosis. Diagnostic Microbiology and Infectious Disease, 56, 161-165. https://doi.org/10.1016/j.diagmicrobio.2006.03.012
- Tenter, A., Heckeroth, A.R. and Weiss, L.M. (2000) Toxoplasma gondii: From Animals to Humans. International Journal for Parasitology, 30, 1217-1258. https://doi.org/10.1016/S0020-7519(00)00124-7
- Olariu, T., Remington, J.S., McLeod, R., Alam, A. and Montoya, J.G. (2011) Severe Congenital Toxoplasmosis in the United States: Clinical and Serologic Findings in Untreated Infants. The Pediatric Infectious Disease Journal, 30, 1056-1061. https://doi.org/10.1097/INF.0b013e3182343096
- Hezard, N., Marx-Chemla, C., Foudrinier, F., Villena, I., Quereux, C., Leroux, B., Dupouy, D., Talmud, M. and Pinon, J.M. (1997) Prenatal Diagnosis of Congenital Toxoplasmosis in 261 Pregnancies. Prenatal Diagnosis, 17, 1047-1054. https://doi.org/10.1002/(SICI)1097-0223(199711)17:11 3.0.CO;2-Q
- Mcleod, R., Mack, D., Foss, R., Boyer, K., Withers, S., Levin, S. and Hubbell, J. (1992) Levels of Pyrimethamine in Sera and Cerebrospinal and Ventricular Fluids from Infants Treated for Congenital Toxoplasmosis. Toxoplasmosis Study Group. Antimicrobial Agents and Chemotherapy, 36, 1040-1048. https://doi.org/10.1128/AAC.36.5.1040
- Gilbert, R., Dunn, D., Wallon, M., Hayde, M., Prusa, A., Lebech, M., Kortbeek, T., Peyron, F., Pollak, A. and Petersen, E. (2001) Ecological Comparison of the Risks of Mother-to-Child Transmission and Clinical Manifestations of Congenital Toxoplasmosis according to Prenatal Treatment Protocol. Epidemiology & Infection, 127, 113-120. https://doi.org/10.1017/S095026880100560X